Population Pharmacokinetics of Lamotrigine with Data from Therapeutic Drug Monitoring in German and Spanish Patients with Epilepsy

  1. Elger, Christian E 2
  2. Buelga, Dolores Santos 1
  3. Domínguez-Gil, Alfonso 1
  4. Santos-Borbujo, José 1
  5. García, María José 1
  6. Rivas, Nuria 1
  7. Otero, María José 1
  1. 1 Universidad de Salamanca
    info

    Universidad de Salamanca

    Salamanca, España

    ROR https://ror.org/02f40zc51

  2. 2 Klinik für Epileptologie, Universitätsklinikum Bonn, Bonn, Germany
Revista:
Therapeutic Drug Monitoring

ISSN: 0163-4356

Año de publicación: 2008

Volumen: 30

Número: 4

Páginas: 483-489

Tipo: Artículo

DOI: 10.1097/FTD.0B013E31817FD4D4 GOOGLE SCHOLAR

Otras publicaciones en: Therapeutic Drug Monitoring

Referencias bibliográficas

  • Eadie, (1998), Br J Clin Pharmacol, 46, pp. 185, 10.1046/j.1365-2125.1998.00769.x
  • Tomson, (2007), Cochrane Database Syst Rev, 1, pp. CD002216
  • Johannessen, (2006), Clin Pharmacokinet, 45, pp. 1061, 10.2165/00003088-200645110-00002
  • Eadie, (2001), Br J Clin Pharmacol, 52, pp. 11S
  • Johannessen, (2003), Ther Drug Monit, 25, pp. 347, 10.1097/00007691-200306000-00016
  • Jiao, (2004), J Clin Pharm Ther, 29, pp. 247, 10.1111/j.1365-2710.2004.00557.x
  • Delgado Iribarnegaray, (1997), Ther Drug Monit, 19, pp. 132, 10.1097/00007691-199704000-00003
  • Bondareva, (2004), J Clin Pharm Ther, 29, pp. 105, 10.1111/j.1365-2710.2003.00538.x
  • Blanco-Serrano, (1999), Biopharm Drug Dispos, 20, pp. 233, 10.1002/(SICI)1099-081X(199907)20:5<233::AID-BDD179>3.0.CO;2-5
  • Serrano, (1999), J Clin Pharm Ther, 24, pp. 73, 10.1046/j.1365-2710.1999.00202.x
  • Yukawa, (1997), J Clin Pharmacol, 37, pp. 1160, 10.1002/j.1552-4604.1997.tb04301.x
  • Banfield, (1996), Ther Drug Monit, 18, pp. 19, 10.1097/00007691-199602000-00004
  • Botha, (1995), Eur J Clin Pharmacol, 48, pp. 381, 10.1007/BF00194954
  • Mullens, (1998), Clin Drug Invest, 16, pp. 125, 10.2165/00044011-199816020-00005
  • Biton, (2005), Neurology, 65, pp. 1737, 10.1212/01.wnl.0000187118.19221.e4
  • Goa, (1993), Drugs, 46, pp. 152, 10.2165/00003495-199346010-00009
  • Rogawski, (2004), Nat Rev Neurosci, 5, pp. 553, 10.1038/nrn1430
  • Perucca, (2005), Epilepsia, 46, pp. 31, 10.1111/j.1528-1167.2005.463007.x
  • Chong, (2002), Ann Pharmacother, 36, pp. 917, 10.1345/aph.1A252
  • Morris, (1998), Br J Clin Pharmacol, 46, pp. 547, 10.1046/j.1365-2125.1998.00835.x
  • Benetello, (2002), Eur Neurol, 48, pp. 200, 10.1159/000066165
  • Grasela, (1999), J Clin Pharmacol, 39, pp. 373, 10.1177/00912709922007949
  • Gidal, (2000), Epilepsy Res, 42, pp. 23, 10.1016/S0920-1211(00)00160-1
  • Hussein, (1997), Br J Clin Pharmacol, 43, pp. 457, 10.1046/j.1365-2125.1997.00594.x
  • Chan, (2001), Ther Drug Monit, 23, pp. 630, 10.1097/00007691-200112000-00006
  • Chen, (2000), Br J Clin Pharmacol, 50, pp. 135, 10.1046/j.1365-2125.2000.00237.x
  • Castel-Blanco, (2001), J Chromatography B Biomed Sci Appl, 755, pp. 119, 10.1016/S0378-4347(01)00044-5
  • Cohen, (1987), Clin Pharmacol Ther, 42, pp. 535, 10.1038/clpt.1987.193
  • Rambeck, (1993), Clin Pharmacokinet, 25, pp. 433, 10.2165/00003088-199325060-00003
  • Perucca, (1999), Epilepsia, 40, pp. S7, 10.1111/j.1528-1157.1999.tb02088.x
  • Jonsson, (1999), Comput Methods Programs Biomed, 58, pp. 51, 10.1016/S0169-2607(98)00067-4
  • Vozeh, (1990), J Pharmacokinet Biopharm, 18, pp. 161, 10.1007/BF01063558
  • Garnett, (1997), J Child Neurol, 12, pp. 10, 10.1177/0883073897012001041
  • Armijo, (1999), Ther Drug Monit, 21, pp. 182, 10.1097/00007691-199904000-00008
  • Froscher, (2002), Epileptic Disord, 4, pp. 49
  • Gidal, (1997), Epilepsia, 38, pp. 260, 10.1111/j.1528-1157.1997.tb01111.x
  • Kilpatrick, (1996), Epilepsia, 37, pp. 534, 10.1111/j.1528-1157.1996.tb00605.x
  • Perucca, (2000), Clin Pharmacokinet, 38, pp. 191, 10.2165/00003088-200038030-00001
  • Biton, (2006), Expert Opin Drug Metab Toxicol, 2, pp. 1009, 10.1517/17425255.2.6.1009
  • Almeida, (2006), Eur J Clin Pharmacol, 62, pp. 737, 10.1007/s00228-006-0144-9
  • Grasela, (1991), J Pharmacokinet Biopharm, 19, pp. 25S, 10.1007/BF01371006
  • Posner, (1991), J Pharm Med, 1, pp. 121
  • Bialer, (2005), Ther Drug Monit, 27, pp. 722, 10.1097/01.ftd.0000179854.16846.67
  • Weintraub, (2005), Arch Neurol, 62, pp. 1432, 10.1001/archneur.62.9.1432
  • Rambeck, (1996), Clin Pharmacokinet, 31, pp. 309, 10.2165/00003088-199631040-00006
  • Bottiger, (1999), Ther Drug Monit, 21, pp. 171, 10.1097/00007691-199904000-00006
  • Kanner, (2000), Neurology, 55, pp. 588, 10.1212/WNL.55.4.588
  • Mataringa, (2002), Ther Drug Monit, 24, pp. 631, 10.1097/00007691-200210000-00009
  • Anderson, (1996), Clin Pharmacol Ther, 60, pp. 145, 10.1016/S0009-9236(96)90130-7
  • Perucca, (2006), Clin Pharmacokinet, 45, pp. 351, 10.2165/00003088-200645040-00002